Mifegyne (Mifepristone)

Mifepristone, the active ingredient in Mifegyne, is a progesterone receptor antagonist presented as an oral tablet for oral use. It is employed for the medical termination of early pregnancy up to ten weeks gestation and for cervical ripening prior to surgical procedures.

GNH USA supplies Mifegyne as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory support for global distribution.

Mifepristone acts on progesterone‑dependent pathways and is indicated for the following clinical situations:

- Medical termination of early pregnancy (up to 10 weeks gestation): induces abortion by disrupting progesterone support of the gestational sac. - Cervical ripening prior to surgical procedures: facilitates cervical softening to aid dilation and evacuation. - Cushing's syndrome (in combination therapy): contributes to reduction of cortisol production when used with other agents.

Mifepristone may cause a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Vaginal bleeding: irregular or heavy bleeding. - Cramping: uterine pain or discomfort. - Fatigue: feeling of tiredness or weakness.

Serious or Rare Side Effects: - Severe infection: signs of sepsis or fever. - Heavy hemorrhage: excessive blood loss requiring medical intervention. - Allergic reaction: rash, swelling, or anaphylaxis.

Before prescribing Mifegyne, clinicians should consider several safety and handling precautions. - Confirm gestational age: ensure pregnancy is ≤10 weeks by ultrasound. - Evaluate for ectopic pregnancy: rule out before use. - Assess for chronic corticosteroid therapy: avoid abrupt discontinuation. - Monitor for anemia: check hemoglobin due to potential bleeding. - Counsel on contraception: advise effective contraception after treatment. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Mifepristone can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - CYP3A4 inducers (e.g., rifampin, carbamazepine): reduce mifepristone plasma levels, compromising effectiveness. - Anticoagulants (e.g., warfarin): increased risk of bleeding when combined with abortion‑related hemorrhage.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise mifepristone concentrations, heightening side‑effect risk. - NSAIDs: may exacerbate gastrointestinal discomfort. - Hormonal contraceptives: reduced efficacy when used concurrently; advise backup method.